—] Shares of Common Stock Warrants to Purchase [—] Shares of Common Stock and Warrants to Purchase [—] Shares of Common Stock IDERA PHARMACEUTICALS, INC. PURCHASE AGREEMENTPurchase Agreement • May 1st, 2013 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) [—] authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, (ii) warrants of the Company, in the form set forth in Exhibit C hereto, to purchase [—] shares of Common Stock at an exercise price of $[—] per share (the “Firm Warrants”) and (iii) warrants of the Company, in the form set forth in Exhibit D hereto, to purchase [—] shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”). Each Firm Share is being sold together with a Firm Warrant to purchase $[—] of a share of Common Stock at an exercise price of $[—] per share. Each Pre-Funded Warrant is being sold together with a Firm Warrant. The Firm Shares, Firm Warrants and the Pre-Funded Warrants purchased pursuant to this Agreement are herein coll
AGREEMENTWarrant Agreement • May 1st, 2013 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This Agreement (this “AGREEMENT”) is entered into as of April 30, 2013 by and among Idera Pharmaceuticals, Inc., a Delaware corporation (the “COMPANY”), Pillar Pharmaceuticals I, L.P. (“PILLAR I”), Pillar Pharmaceuticals II, L.P. (“PILLAR II”), and Participations Besancon (“BESANCON” and, together with Pillar I and Pillar II, the “PILLAR ENTITIES”). The parties hereby agree as follows:
